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Editor’s Introduction
The discipline of gastroenterology, hepatology and pancreatology has changed dramatically 
since its inception as a specialty of internal medicine. The specialty originally focused and 
pursued an understanding of the pathology and physiology of the gastrointestinal tract, liver 
and pancreas scientifically, something which is still in active evolution.. We began to 
comprehend gut motility, stomach acid secretion, the epidemiology of digestive cancers, 
autoimmune diseases of the gut, pancreas and liver, and how infectious diseases are 
transmitted and affect the GI tract. Treatment slowly became possible with the acquired 
knowledge, and created approaches for therapeutics. Histamine type 2 blockers and proton 
pump inhibitors, nucleotide and nucleoside analogs, immune modulators, and a myriad of 
antibiotics have been studied and used effectively to alleviate patient suffering from GI 
diseases. Radiological imaging helped determine the absence, presence, or extent of disease 
non-invasively. Endoscopy of the alimentary tract and its related growing list of special 
devices have provided a huge leap forward in caring for patients with GI disease, allowing 
direct visualization of and sampling from the GI tract, and providing an avenue for direct 
therapeutic intervention.
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We have now entered the genomic era, providing another leap forward in the care of patients 
with GI diseases. This era commenced with the identification genetic mutations as the basis 
of Mendelian-inherited diseases involving the GI tract, such as familial adenomatous 
polyposis [1,2], cystic fibrosis [3–5], and genetic hemochromatosis [6]. The genetic 
information could be predictive if one carried the mutation; it could be also be predictive to 
family members when they did not carry the mutation, foregoing unnecessary surveillance 
efforts and applying those healthcare resources aptly to mutant carriers. Genetic information 
has progressed dramatically and now extends past heritable diseases; it applies to many GI 
conditions in terms of risk (e.g. genome wide association studies or GWAS, or the presence 
or absence of a mutation directly within tumor tissue), prediction of biological behavior, 
outcome and survival, and in the approach and use of therapeutics (e.g. cetuximab in wild 
type KRAS colorectal cancer, or 6-thioguanine and 6-methylmercaptopurine metabolite 
levels for optimal use of azathioprine or 6-mercaptopurine). The field is rapidly evolving. A 
convergence of advancing knowledge of GI tract disease, technical advances and reduced 
costs for next generation sequencing and other analytic technologies such as proteomics and 
metabolomics, easier access to sampling human tissue with advances in image-directed 
biopsies and minimally invasive tissue removal, and a growing number of interventions 
discovered to improve the health of patients with GI diseases make this era an exciting time 
for helping our patients and fundamentally changing our GI practices.
Biomarkers are a key part of precision (personalized or individualized) medicine. Molecular 
biomarkers are derived from the genetic, genomic and other high-throughput platforms in 
analysis of blood, tissue, fecal, urine or other biological material that can inform the 
practitioner on the next best course of action for the individual patient [7]. Biomarkers 
ideally lead to prescriptive targeted treatment changes that can improve the outcome of 
patients with GI disease; this is the essence and part of the definition of precision medicine 
[8]. Biomarkers can also be diagnostic or prognostic, being more informative for a clinical 
course rather than a targeted individualized treatment prescription. The assumption and 
reality is that GI patients with a specific disease are biologically heterogeneous, and 
molecular biomarkers can differentiate patients into subtype groupings of more 
homogeneous individuals sharing an actionable characteristic amenable to molecularly 
targeted therapies beneficial to that subgroup or individual. Both biomarkers and targeted 
individualized therapies are the cornerstone of President Obama’s Precision Medicine 
Initiative put forth in early 2015 [9]. This initiative aims to further revolutionize the practice 
of medicine by generating additional scientific evidence to move the concept of precision 
medicine into everyday clinical practice. Parallel and complimentary ventures such as the 
100,000 Genomes Project in the UK aim to identify novel genetic diagnoses and create 
opportunities for the use of genomics in healthcare [10].
This special issue of Gastroenterology lays a foundation and provides a current 
understanding to the approach to precision medicine for several GI disorders, a timely topic 
given the growing international investments in personalized care. We as editors of this 
special issue, along with the entire Gastroenterology Board of Editors, selected the topic of 
genetics, genetic testing, and biomarkers in digestive diseases because of the rapid advances 
in these topics among the GI diseases over just the past few years. Recent studies outlined in 
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many of the articles within this special issue highlight how fast information has moved, and 
how quick biomarkers and potential therapeutic targets for treatment purposes are lining up 
for phased human clinical studies, pharmaceutical testing portfolios, and routine patient use. 
The transformation from bench to practice has been greatly accelerated with newer and 
cheaper genomic analytic capabilities and information technologies, and rapid dissemination 
of information. New molecular biomarker tests are being put out to the clinical commercial 
market on a regular basis. Many aspects of this rapid change have and will continue to 
become part of daily clinical GI practice.
For this special issue of Gastroenterology, we recruited leading authorities to update our 
readers in the genetics, genetic testing, and biomarkers of digestive diseases. The 12 reviews 
and 2 commentaries in this issue cover many aspects of the GI tract, hepatobiliary system 
and pancreas. The two commentaries are more general than disease-focused, and deal with 
the generation and recording of genetic information. The commentary by Ananthakrishnan 
and Lieberman examines the current and future ideal use of electronic health records for 
genetic and biomarker information that pertains to the practitioner and researcher, 
laboratory, and patient [11]. Ngeow and Eng’s commentary addresses a path forward in the 
post-genomic area, including the examination of gene-gene or gene-environment 
interactions, and clinical implementation of genomics [12]. Among the 12 disease-focused 
reviews, four articles examine biomarkers and genetics and their clinical application in 
colorectal cancer (CRC). Stoffel and Boland provide genetic testing insights in inherited 
forms of CRC [13], and Carethers and Jung highlight the genetics and potential biomarkers 
for use in patients with sporadic CRC [14]. Okugawa, Grady and Goel showcase how 
epigenetic alterations in CRC provide biomarkers for patient care [15], and Robertson and 
Imperiale review the clinical application of biomarkers within stool tests for CRC screening 
[16]. Three articles focus on the rapidly advancing use of genetics and biomarkers for 
inflammatory bowel disease (IBD). McGovern, Kugathasan and Cho provide an update on 
GWAS data from large IBD studies [17], Dubinsky and Braun showcase the use of 
microbial biomarkers for IBD diagnosis [18], and Sands highlights inflammatory biomarkers 
for IBD [19]. Two articles focus on the liver: Pietrangelo reviews classic hemochromatosis 
genetics and testing [20], and Zucman-Rossi, Villaneuva, Nault and Llovet provide a 
comprehensive review of the genetics and biomarkers for hepatocellular carcinoma [21]. 
The remaining three reviews highlight the esophagus, stomach, and pancreas. Reid, Paulson 
and Li present the most up-to-date genetic analyses of Barrett’s esophagus and esophageal 
adenocarcinoma [22]. Tan and Yeoh supply the latest insights of the genetics of gastric 
adenocarcinoma [23], while Whitcomb, Shelton and Brand present the latest on the 
biomarkers and genetics of inherited and sporadic forms of pancreatic cancer [24]. We are 
very grateful to the contributing authors as well as the insightful manuscript reviewers and 
editorial staff for their time and energy in creating these outstanding articles with useful 
figures and tables for the readers of Gastroenterology.
We hope that readers of this special issue of Gastroenterology will find it full of new 
insights into this rapidly moving field in clinical GI practice. We hope you enjoy the up-to-
date information, and see the alignment with current and future aspects of the Precision 
Medicine Initiative and the other related global efforts. We trust that this issue provides a 
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new and timely reference as precision medicine, biomarkers, and genetics move more fully 
into GI clinics to direct patient care.
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